The purpose of this review is to describe the most recent literature on outcomes and issues associated with HIV self-testing (HIVST).
INTRODUCTION
A high proportion of people living globally with HIV remain undiagnosed. Despite intensive interventions to increase testing over the past decade, 17.1 million of the estimated 36.9 million people living with HIV worldwide in 2014 remained undiagnosed [1] . This has implications not just for individual health, with the results of the START trial in 2015 indicating that antiretroviral therapy (ART) is beneficial at any CD4 þ cell count, but also for onwards transmission of HIV, with 60-80% of transmission thought to occur from those as yet undiagnosed and often in the early stages of infection in which risk of onwards transmission is greater [2] [3] [4] [5] .
The 'Test and Treat' approach has been enshrined in the UNAIDS global 90-90-90 targets, which aim by 2020 to achieve 90% of people with HIV being diagnosed, 90% taking ART and 90% of those treated achieving virological suppression [6] . The first '90' is the largest gap with only 53% of those living with HIV currently being diagnosed. Efforts to increase testing rates have led to expansion of testing opportunities and testing interventions to meet the needs of a range of different groups in a variety of contexts (Table 1) [7] [8] [9] [10] . HIV self-testing (HIVST) is simply the latest iteration of testing modalities.
SCOPE OF THIS REVIEW
The field of literature surrounding HIVST is evolving rapidly. Although some key literature has been formally published, much of the most up-to-date and relevant evidence comes from conference abstracts. Understanding key elements of HIVST, including values and preferences in key populations most impacted by HIV, is crucial. In terms of HIVST outcomes, feasibility studies, pilot HIVST projects and non-randomized controlled trial (non-RCT) intervention studies have occurred in a variety of settings, as have several RCTs. Both RCTs and nonRCTs typically focus on interventions to detect prevalent infections or increase testing frequency. Evidence on harm is limited, but important work is emerging. Economic evidence including cost-effectiveness analysis is very much in the nascent stages of development.
The purpose of this review is to describe the most recent literature on outcomes and issues associated with HIVST.
HIV SELF-TESTING

Regulatory approval and policy
We define HIVST as when an individual takes his/ her own sample, processes it and interprets his/her own result. A reactive result from HIVST is not a diagnosis; this requires the individual to subsequently attend a testing facility for confirmatory HIV testing and linkage to care. Self-tests for a variety of other conditions are already available to the general public. HIV has long been viewed as an exceptional disease by policymakers and clinicians, and this exceptionalism meant that early in the epidemic, HIVST was banned in many countries due to concerns over the potential for self-harm in the absence of effective treatments and the potential for coercive use [11] .
In recent years, the shift in HIV to a chronic manageable disease with near-normal life expectancy [12, 13] through highly effective ART has led to changing attitudes towards the impact of HIV diagnosis among clinicians and populations affected by HIV. These changes have led to a more permissive policy environment, with increasing numbers of countries enacting laws or repealing legislation making rapid diagnostic tests (RDTs) for self-use available. The UK, for example, legalized HIVST on 1 April 2014, with the first commercially available test released the following year (BioSure HIV Self Test; BioSure, Nazeing, UK). HIVST is permitted with regulated tests available from the private sector in other countries such as the United States, France, Belgium and Brazil [14] . Other countries such as Australia have policies permitting HIVST, but no tests are as yet approved by the necessary regulatory agencies. Many more nations have no official policies on the technology, but unregulated HIVST kits and RDTs intended for clinical use are often available either online or through pharmacies, raising concerns about quality [14] .
In efforts to continue expanding HIV testing, HIVST has been officially adopted on a global policy level, with the WHO incorporating HIVST into their Consolidated Guidelines on HIV testing services in July 2015 [15] .
Potential benefits
HIVST has been promoted as a low-cost alternative to facility-based testing, potentially reducing barriers such as stigma and opportunity cost while boosting patient choice and enhancing autonomy, thereby potentially expanding testing to new groups
KEY POINTS
A high proportion of people living globally with HIV remain undiagnosed, despite intensive interventions to increase testing over the past decade.
HIVST has the potential to increase rates of HIV testing and is acceptable to a range of populations in a variety of contexts.
Studies are ongoing to determine the efficacy of HIVST to increase rates of HIV diagnosis, particularly in highincidence groups.
There is currently little evidence of harms related to HIVST, but concerns remain about the reliability of currently available HIVST kits (especially during very early HIV infection) and on linkages to care for confirmatory testing after a reactive HIVST result.
Data on the cost-effectiveness of HIVST to increase rates of HIV diagnosis are currently limited. and enabling increased testing frequency in those at highest risk [16] . HIVST also has applications in intensive combination HIV prevention initiatives such as the targeted expansion of testing, treatment and preexposure prophylaxis (PrEP) [16, 17] . HIVST is available using both a whole blood sample, usually from a finger prick, or using oral fluid.
Understanding implementation contexts: values and preferences
In general, studies which seek to understand how populations might accept HIVST tend to include participants who have not actually experienced HIVST themselves, and the intervention is therefore hypothetical. Understanding this evidence remains worthwhile because it provides an indication of how populations are likely to engage with the technology and how interventions should be delivered to ensure that they are acceptable.
Men who have sex with men (MSM) [and to a lesser extent transgender women and female sex workers (FSWs)] in high and middle-income settings are well represented in literature around HIVST acceptability as well as values and preferences. There are fewer current data from Europe. General populations are also less well represented in available data, although there is some evidence emerging from east and southern Africa [18, 19] .
Recent studies report high acceptability of HIVST for MSM across a range of settings. Emerging evidence from Peru [20, 21] , Scotland [22] , the United States [23, 24] , Vietnam [25] and Mexico [26] report that MSM find HIVST highly acceptable, with moderate acceptability observed in Hong Kong [27] . In a recent cross-sectional study in England, HIVST was the second most preferred location for future HIV testing and tended to have greater popularity amongst MSM less likely to test at a frequency in line with national guidelines [28] .
Confidentiality, convenience, immediacy and the opportunity to increase testing frequency are commonly cited benefits of HIVST [22] [23] [24] [25] 29 && , [30] [31] [32] . Barriers tend to be concerns around dislocation from care pathways, the possibility of coercive testing practices, perceived issues with self-efficacy as well as kit accuracy [31, 33, 34] .
A systematic review conducted by Figueroa et al. [29 && ] provides an excellent analysis of the relative preferences of various intervention components among key populations. Evidence suggests that oral fluid RDTs are marginally preferred over finger stick or whole blood tests, although this tends to vary across country income settings and population [29 && ]. For example, a recent UK study found that MSM preferred HIVST kits using a blood sample due to concerns around accuracy with oral fluid HIVST [31] . In a study in Vietnam, MSM and FSWs preferred oral fluid HIVST, whereas people who inject drugs (PWID) preferred blood-based kits [25] . In work from the United States conducted with an ethnically diverse group of high-risk MSM, more frequent testers preferred blood-based testing, whereas men who tested less frequently preferred oral fluid HIVST [35] .
Demonstrating impact of HIV self-test: outcomes from pilot projects and randomized controlled trials A range of feasibility studies, pilot projects and trials have provided data on the feasibility and impact of providing HIVST to different groups through an array of intervention designs. Although the aims for each study vary (as does quality, particularly in feasibility and pilot studies), intervention designs tend to fall into one of two categories. The first is to detect long-standing prevalent infections among groups who have never tested or who test suboptimally. The second is to increase frequency of testing to decrease the time between acquiring HIV infection and diagnosis, particularly in risk groups with high incidence. Evidence surrounding linkage to care in RCTs remains limited. Table 2 presents key RCTs; planned, ongoing and completed.
Detection of prevalent infections
Feasibility and pilot HIVST studies provide some evidence that HIVST will likely detect undiagnosed prevalent infections in individuals who test suboptimally or have never tested, although it remains unclear if HIVST is more effective than other testing options to meet this aim. Projects in the United States and the United Kingdom that focused on reaching groups who have not previously tested or have difficulty accessing services seem to be successful in reaching MSM online [36, 37] and to an extent in sex on premise venues [38] . In Vietnam, community distribution was successful in reaching MSM, FSWs and PWIDs in urban and rural settings [25] .
Of particular interest is a cohort study conducted in Kenya that provided women with a varying number of HIVST kits to distribute to their sexual partners [39 && ]. Of 58 women recruited in antenatal care, 91% (53) distributed a kit to their partner, as did 86% (91) of 106 women in postpartum care and 75% (64) of 85 FSWs [39 && ]. In an RCT distributing HIVST kits to pregnant women and their partners in Kenya, a significantly greater proportion of those in the HIVST arm tested for HIV compared with those randomized to standard of www.co-infectiousdiseases.comcare (SoC) facility-based testing. More male partners of women in the intervention group tested (90.8 vs 51.7%) and higher levels of couples testing also occurred in those in the intervention arm (75.4 vs 33.2%) [40] . It is important to note that figures in both studies are based on participants' reports of their partners' testing behaviour and must therefore be interpreted with caution.
Reducing interval between infection and diagnosis Efforts to increase the frequency with which at-risk groups with high HIV incidence test are central to aspirations around the expansion of HIVST. Increased frequency of testing is a key benefit often repeated in values and preferences studies conducted with key populations. Non-RCT projects that have provided participants with a number of HIVST kits with instructions to test frequently have shown that distribution in line with this intervention approach is feasible amongst transgender women in San Francisco [32] and MSM in Brazil and Peru [21] . RCT evidence in this area is not strong, largely because studies have been underpowered to assess rates of diagnosis, and therefore frequency of testing has been used as a proxy measure. In Seattle, MSM tested significantly more frequently when provided with multiple HIVST kits compared with SoC (5.3 tests compared with 3.6 over 15 months) [41] . The study was too small (n ¼ 230) to show an effect on increasing HIV diagnosis [41] . These findings were repeated in MSM in Australia, which showed increased testing frequency among the self-testing group, which did not reduce attendance in sexually transmitted infection (STI) indicating that men in this study used HIVST largely as a supplementary option [42 & ]. Encouragingly, in both these RCTs, testing frequency was increased in both frequent and infrequent testers.
Linkage to care
Linkage to care for confirmatory testing is critical following a reactive result from HIVST. A cluster randomized trial in Malawi reported that 56.3% (524/930) of people who had a reactive HIVST subsequently linked to care for confirmatory testing ]. There is as yet very limited evidence from high-income settings of linkage rates after HIVST, though a planned trial, as detailed below, aims to provide data in this area.
Ongoing and planned studies Two studies are worth noting. The HIV Self-testing Africa (STAR) Project is a 23 million USD 4-year study taking place in Malawi, Zambia and Zimbabwe, which will be the largest investigation of HIVST to date. This project will evaluate accuracy, uptake, case finding and linkage to care through a variety of models of HIVST delivery in these three countries.
The planned SELPHI study in the United Kingdom will be the first RCT that attempts to address questions on both the ability of HIVST to detect prevalent infections and also to reduce the time between infection and diagnosis and aims to recruit 10 000 MSM in England and Wales from early 2017. The primary outcome is rates of HIV diagnosis as determined through confirmatory testing and linkage to care. This RCT will provide vital evidence for future policy-makers in high-income settings and those working with key populations on the efficacy and cost-effectiveness of HIVST in increasing rates of HIV diagnosis.
TECHNOLOGICAL ISSUES: SENSITIVITY OF HIV SELF-TESTS, PARTICULARLY IN EARLY HIV INFECTION
Reliable use of HIVST kits has been reported as highly variable in observed studies (25-99.2%) [18, 44, 45] , though groups used in these studies are not necessarily reflective of those likely to need or use HIVST, which makes critical assessment of these results complex. However, sensitivity and specificity estimates for HIVST when used by selftesters are high, though would appear to be higher for whole blood-based HIVST compared with oral fluid-based tests (96.2-100% compared with 80-100%) [46] . Promisingly, repeated exposure to and use of HIVST seems to increase the confidence and ability of individuals to perform the tests correctly [19, 23, 47] .
Perhaps a more pressing concern, reflected by policy-makers, commissioners and patients, is that HIVST kits have a lower sensitivity (and specificity) than those currently available in clinical settings, particularly in the period of early HIV infection known as acute infection. The time from initial HIV infection to detection of infection (window period) depends on the properties of the test used. Figure 1 demonstrates the range of window periods before detection of HIV infection depending on whether antibody, antibody/antigen combination or HIV RNA tests are used. Currently available HIVST products are classed as second-generation tests (antibody tests that are not laboratory tests), highlighting that HIVST is an innovation using older generation assays.
Manufacturers of current blood-based and oral fluid-based HIVST give window periods of up to 3 months for their products. The OraQuick In-Home HIV Test (OraSure Technologies, Inc., Bethlehem, Pennsylvania, USA) also reports data indicating 95-98% detection of new HIV infection at 6 weeks and 99% by week 12 [48] . Blood-based antibody tests are likely to have slightly shorter window periods. In high-risk populations, the window period of current tests is particularly troubling, with mathematical modelling suggesting that widespread use of oral HIVST in high-risk populations could potentially increase HIV prevalence due to the long window period and potential false sense of security from non-reactive HIVST results leading to greater sexual risk-taking [49] .
One of the potential utilities of HIVST is for those who require frequent HIV testing such as people taking PrEP. There is concern however that using an oral-based HIVST in particular may lead to an increased rate of false negative tests in early infection. During the Bangkok Tenofovir PrEP Study, staff reported nonreactive monthly oral fluid HIVST (OraQuick) results for eight participants (20% of all seroconversions in the study) for more than 3 months (84 days) after HIV infection. Participants receiving tenofovir in this study took longer to develop a reactive OraQuick HIVST kit (191.8 days) than participants receiving placebo (16.8 days) (P ¼ 0.02) [50] . This may be due to the fact that the OraQuick test contains only a single glycoprotein antigen (antigp41), so it will not identify HIV-infected individuals who fail to mount a substantial antibody response to that particular antigen, perhaps due to the presence of ART. This could also be a potential issue for people with diagnosed HIV who test using oral fluid HIVST to double check their status. Receiving a false non-reactive result in this way could cast doubt on whether they have HIV, perhaps leading to attrition from the care cascade and interruption of treatment. It is likely however that HIVST kits, particularly blood-based products, will improve in time with antigen detection, thus increasing sensitivity and specificity.
POTENTIAL FOR SOCIAL HARMS FROM HIV SELF-TESTING
When considering implementation of HIVST, the potential for harm among the self-tester and the broader population are often iterated concerns. A systematic review in 2014 of a variety of self-diagnostics (including 49 articles on HIVST) found very little evidence of any harm occurring in self-testing [51] . However, ongoing vigilance is required for any potential negative effects as HIVST is expanded in at-risk populations.
A further concern around HIVST that remains is the potential for intimate partner violence (IPV) and coercive testing, though there is little current evidence in this area. In a recent study involving 600 women in Kenya in which pregnant women were given HIVST kits for themselves and their partner, low and equal rates of IPV were observed in both the HIVST and SoC arms (one incident in each) [40] . However, women who felt that they were at risk of IPV were excluded from this study. Coercive testing has been described in Malawi, with more men than women reporting having been coerced [33, 52] , but evidence suggests that this did not impact on intervention acceptability. In some cases, coercion was felt to be beneficial in that it reduced personal barriers to testing indicating that 'coercion' conceptually must be understood in the social context within which it occurs [33] .
FURTHER AVENUES OF EXPLORATION: ECONOMIC EVALUATION
Evidence that HIVST will save costs to health services is currently lacking, particularly in resourcerich settings, though planned studies aim to fill this gap.
In sub-Saharan Africa, in a substudy from the cluster RCT in Malawi, the mean society cost of HIVST compared with facility-based testing has been estimated to be US$9.2 [95% confidence interval (CI): US$9.1-9.3] vs US$11.8 (95% CI: US$10.8-12.9). The cost per infection detected was higher through HIVST (US$97.5) than for facilities, which ranged between US$25.2 and 76.1 [53] .
Recently published evidence from Cambiano et al. [54 & ] assessed the potential impact and costeffectiveness of HIVST in Zimbabwe estimating two models in which HIVST was not introduced, and one in which it was. They estimated that the introduction of HIVST alongside existing testing interventions would save $75 million while averting 7000 disability-adjusted life-years over 20 years. This work also found however that should linkage to cascades of care be significantly impacted, ART CD4 þ thresholds lowered or if HIVST cost significantly more than the scenario estimated cost of $3, then scenarios could emerge in which HIVST was not cost-effective when compared with the reference scenario.
CONCLUSION
Based on this review of the most recent evidence, HIVST is clearly acceptable and feasible to deliver to a range of populations in a variety of settings. In addition, HIVST has a role alongside other existing service provision, but it is imperative to understand this in particular demographic, cultural and health systems contexts, as well as the values and preferences of the intended end users. Although HIVST seems able to encourage testing in individuals who test suboptimally and can increase the frequency at which some individuals test, it is less clear whether it is more effective or cost-effective at detecting prevalent infections or reducing the interval between HIV infection and diagnosis for those in high-incidence groups than current testing provision. Rates of linkage to care, an essential step following a reactive result with HIVST, are unclear particularly in resource-rich settings.
Improvements in kit sensitivity with shorter window periods, potentially with antibody/antigen combinations, are vital to serve the needs of individuals, particularly those from key populations with high incidence of infection. It is currently uncertain to what degree harms, if any, occur from HIVST and what form these harms may take. Social sciences should be key in responding to questions about harms so that these are understood from the perspective of those utilizing the intervention. Economic evaluation of HIVST is in nascent stages and should be a key priority area for moving forward.
